J Robert

Summary

Affiliation: Institut Bergoni
Country: France

Publications

  1. pmc Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines
    F Moisan
    , , 229 Cours de l Argonne, 33076, Bordeaux Cedex, France
    Br J Cancer 95:906-13. 2006
  2. pmc The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models
    N Faur
    Département de Parmacologie, INSERM U916, Bordeaux, France
    Br J Cancer 101:350-6. 2009
  3. pmc Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
    E Rouits
    Laboratoire d Oncopharmacologie, Centre Paul Papin, 2 rue Moll, Angers 49000, France
    Br J Cancer 99:1239-45. 2008
  4. pmc Evaluation of antiproliferative and anti-inflammatory activities of methanol extract and its fractions from the Mediterranean sponge
    Afef Dellai
    Laboratoire de Pharmacologie des Médicament Anticancéreux, Universite Victor Segalen Bordeaux 2, Institut Bergonie, 229 Cours de l Argonne, Bordeaux Cedex, 33076, France
    Cancer Cell Int 12:18. 2012
  5. ncbi request reprint [What is a targeted therapy? The view of the biologist]
    Jacques Robert
    Laboratoire de pharmacologie des médicaments anticancéreux, Universite Victor Segalen Bordeaux 2, Institut Bergonie, 229 Cours de l Argonne, 33076 Bordeaux Cedex
    Bull Cancer 94:F101-10. 2007
  6. ncbi request reprint Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls
    J Robert
    Universite Victor Segalen Bordeaux 2, Institut Bergonie, 229 cours de l Argonne 33076 Bordeaux, France
    Cell Biol Toxicol 23:27-37. 2007
  7. ncbi request reprint Cancer Therapeutics, Molecular Targets, Pharmacology and Clinical Applications--First International Conference 19-21 February 2004, Florence, Italy
    Jacques Roberts
    Institut Bergonie, 229 Cours de l Argonne, 33076 Bordeaux Cedex, France
    IDrugs 7:301-5. 2004
  8. ncbi request reprint Predicting drug response and toxicity based on gene polymorphisms
    Jacques Robert
    Institut Bergonié and Université Victor Segalen Bordeaux 2, 229 Cours de l Argonne, 33076 Bordeaux Cedex, France
    Crit Rev Oncol Hematol 54:171-96. 2005
  9. ncbi request reprint Multidrug resistance reversal agents
    Jacques Robert
    Institut Bergonie, 229, cours de l Argonne, 33076 Bordeaux Cedex, France
    J Med Chem 46:4805-17. 2003
  10. ncbi request reprint Pharmacogenetics and pharmacogenomics as new tools to optimise cancer chemotherapy
    J Robert
    Universite Victor Segalen Bordeaux 2, Institut Bergonie, 33076 Bordeaux Cedex, France
    J Chemother 16:22-4. 2004

Collaborators

Detail Information

Publications58

  1. pmc Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines
    F Moisan
    , , 229 Cours de l Argonne, 33076, Bordeaux Cedex, France
    Br J Cancer 95:906-13. 2006
    ....
  2. pmc The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models
    N Faur
    Département de Parmacologie, INSERM U916, Bordeaux, France
    Br J Cancer 101:350-6. 2009
    ..For validation, the same study was performed independently on a second panel of tumour cell lines, JFCR-45...
  3. pmc Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
    E Rouits
    Laboratoire d Oncopharmacologie, Centre Paul Papin, 2 rue Moll, Angers 49000, France
    Br J Cancer 99:1239-45. 2008
    ..All these observations may improve the routine use of irinotecan in colorectal cancer patients. UGT1A1 genotyping plus cortisol 6beta-hydroxylation determination could help to determine the optimal dose of irinotecan...
  4. pmc Evaluation of antiproliferative and anti-inflammatory activities of methanol extract and its fractions from the Mediterranean sponge
    Afef Dellai
    Laboratoire de Pharmacologie des Médicament Anticancéreux, Universite Victor Segalen Bordeaux 2, Institut Bergonie, 229 Cours de l Argonne, Bordeaux Cedex, 33076, France
    Cancer Cell Int 12:18. 2012
    ..abstract:..
  5. ncbi request reprint [What is a targeted therapy? The view of the biologist]
    Jacques Robert
    Laboratoire de pharmacologie des médicaments anticancéreux, Universite Victor Segalen Bordeaux 2, Institut Bergonie, 229 Cours de l Argonne, 33076 Bordeaux Cedex
    Bull Cancer 94:F101-10. 2007
    ..This didactic review presents the general aspects of the molecular alterations of cancers, the potential targets which ensue, and the ways presently available to reach them...
  6. ncbi request reprint Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls
    J Robert
    Universite Victor Segalen Bordeaux 2, Institut Bergonie, 229 cours de l Argonne 33076 Bordeaux, France
    Cell Biol Toxicol 23:27-37. 2007
    ..Based upon these various contributions, we can encourage the use of the short-term model of isolated perfused rat heart to screen the preclinical cardiotoxicity of anthracycline molecules, formulations and combinations...
  7. ncbi request reprint Cancer Therapeutics, Molecular Targets, Pharmacology and Clinical Applications--First International Conference 19-21 February 2004, Florence, Italy
    Jacques Roberts
    Institut Bergonie, 229 Cours de l Argonne, 33076 Bordeaux Cedex, France
    IDrugs 7:301-5. 2004
    ..The paradigm of antibiotics and infectious diseases may well serve as a guide for this evolution...
  8. ncbi request reprint Predicting drug response and toxicity based on gene polymorphisms
    Jacques Robert
    Institut Bergonié and Université Victor Segalen Bordeaux 2, 229 Cours de l Argonne, 33076 Bordeaux Cedex, France
    Crit Rev Oncol Hematol 54:171-96. 2005
    ..However, confusion factors may exist between the role of gene polymorphisms in cancer risk or overall prognosis and their role in drug response...
  9. ncbi request reprint Multidrug resistance reversal agents
    Jacques Robert
    Institut Bergonie, 229, cours de l Argonne, 33076 Bordeaux Cedex, France
    J Med Chem 46:4805-17. 2003
  10. ncbi request reprint Pharmacogenetics and pharmacogenomics as new tools to optimise cancer chemotherapy
    J Robert
    Universite Victor Segalen Bordeaux 2, Institut Bergonie, 33076 Bordeaux Cedex, France
    J Chemother 16:22-4. 2004
    ..Pharmacogenetics and pharmacogenomics are acting synergistically for the personalisation of treatments, on the basis of the constitutive singularity of patients and of the molecular characteristics of tumours...
  11. ncbi request reprint MS-209 Schering
    Jacques Robert
    Institut Bergonié and Université Victor Segalen, 229 Cours de l Argonne, 33076 Bordeaux Cedex, France
    Curr Opin Investig Drugs 5:1340-7. 2004
    ..By March 2003, phase II trials in breast cancer and non-small-cell lung cancer had been initiated...
  12. ncbi request reprint [Pharmacogenetics and pharmacogenomics of cancers]
    J Robert
    Institut Bergonié et université Victor Segalen, 229, cours de l Argonne, 33076 Bordeaux, France
    Pathol Biol (Paris) 52:332-7. 2004
    ..Clinical trials, first on a retrospective basis, then on a prospective one, are implemented to validate this approach...
  13. doi request reprint [Biological bases for individualising prescriptions in oncology: the germline genome]
    Jacques Robert
    Unité Inserm 916, Institut Bergonie, Université Victor Segalen Bordeaux II, 229, cours de l Argonne, 33076 Bordeaux Cedex, France
    Bull Cancer 95:911-21. 2008
    ..Clinical trials, first on a retrospective basis, then on a prospective one, are implemented to validate this approach...
  14. doi request reprint [Cell signalling and cancer]
    J Robert
    Universite de Bordeaux, INSERM U916, Institut Bergonie, 33076 Bordeaux Cedex, France
    Bull Cancer 97:1215-22. 2010
    ..We will present here a general classification of the main pathways of cell signalling and some of the recurrent mechanisms used for the transmission of information between cells and inside cells...
  15. ncbi request reprint Resistance to cytotoxic agents
    J Robert
    Institut Bergonié et Université Victor Segalen Bordeaux 2, France
    Curr Opin Pharmacol 1:353-7. 2001
    ....
  16. doi request reprint [Gene polymorphisms]
    J Robert
    INSERM U916, Institut Bergonie, Universite de Bordeaux, 33076 Bordeaux Cedex, France
    Bull Cancer 97:1253-64. 2010
    ..We present afterwards some examples of the role that play polymorphic constitutive variations of the genome in the occurrence of cancer (molecular epidemiology) and the activity of anticancer drugs (pharmacogenetics)...
  17. doi request reprint [Tyrosine kinase inhibitors]
    Jacques Robert
    Université Bordeaux Segalen, Institut Bergonie, Bordeaux Cedex, France
    Bull Cancer 98:1321-34. 2011
    ..This chemical family is in full expansion and several dozens of compounds have entered clinical trials...
  18. ncbi request reprint Long-term and short-term models for studying anthracycline cardiotoxicity and protectors
    Jacques Robert
    Universite Victor Segalen Bordeaux, Institut Bergonie, Bordeaux Cedex, France
    Cardiovasc Toxicol 7:135-9. 2007
    ..Based upon these contributions, we can encourage the use of the short-term model of isolated perfused rat heart to screen the preclinical cardiotoxicity of anthracycline molecules, formulations and combinations...
  19. pmc Expression of MDR1/P glycoprotein in human sarcomas
    B Vergier
    , Bordeaux, France
    Br J Cancer 68:1221-6. 1993
    ..So care must be taken in interpreting results and more sensitive techniques such as the polymerase chain reaction (PCR) could prove useful...
  20. ncbi request reprint Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients
    E Gamelin
    Service d Oncologie Médicale et de Pharmacologie Clinique, Centre Paul Papin, Angers, France
    J Clin Oncol 16:1470-8. 1998
    ..The current study investigated 5-FU therapeutic intensification with individual dose adjustment in a multicentric phase II prospective trial...
  21. pmc Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin
    D Platel
    , Bordeaux, France
    Br J Cancer 81:24-7. 1999
    ..5 mg kg(-1) per injection, despite similar general toxicity symptoms (weight loss, nose bleeding and diarrhoea) at these respective doses. Thus, HMR-1826 appeared about 100-fold less cardiotoxic than doxorubicin...
  22. pmc P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines
    S Huet
    , Bordeaux, France
    Br J Cancer 65:538-44. 1992
    ..These results suggest that classical MDR was the first phenotype selected by doxorubicin in C6 0.001, whereas mechanism(s) of doxorubicin resistance other than classical MDR are added in the most resistant lines...
  23. pmc Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants
    V Pavillard
    , , , 33076 Bordeaux Cedex, France
    Br J Cancer 85:1077-83. 2001
    ..Clinical protocols combining a topoisomerase I and a topoisomerase II inhibitor should be considered with caution because antagonistic effects have been observed with combinations of camptothecin and doxorubicin...
  24. ncbi request reprint Role of daunorubicinol in daunorubicin-induced cardiotoxicity as evaluated with the model of isolated perfused rat heart
    D Platel
    , Bordeaux, France
    Pharmacol Toxicol 88:250-4. 2001
    ..We conclude that daunorubicinol is not responsible for the important cardiac toxicity of daunorubicin...
  25. ncbi request reprint Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network
    S Huet
    Laboratoire d Immunologie Cytométrie, Institut Bergonie, Bordeaux, France
    Cytometry 34:248-56. 1998
    ..This cross-validated multicentric study points out crucial steps for the accuracy and reproducibility of the results, like cell viability, data analysis and expression...
  26. ncbi request reprint Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage
    E Gamelin
    Département d Oncologie Médicale and d Oncopharmacologie, Centre Paul Papin, Angers, France
    J Clin Oncol 17:1105. 1999
    ..To predict 5-FU catabolic deficiencies and toxic side effects, we conducted a prospective study of patients treated for advanced colorectal cancer by high-dose 5-FU...
  27. ncbi request reprint Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia
    R Bellott
    , Bordeaux, France
    Cancer Chemother Pharmacol 47:15-21. 2001
    ..However, the concentration of daunorubicinol appeared to be lower than that found after conventional administration of daunorubicin...
  28. pmc DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer
    G MacGrogan
    Department of Pathology, Institut Bergonie, 229 Cours de l Argonne, 33076 Bordeaux CEDEX France
    Br J Cancer 89:666-71. 2003
    ..Our clinical results confirm in vitro data on the relationship between Topo IIalpha expression and tumour chemosensitivity and thus may have important practical implications...
  29. doi request reprint Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: studies with in vitro models
    Audrey Laroche-Clary
    Universite Victor Segalen Bordeaux 2, INSERM U916 and Institut Bergonié, Bordeaux, France
    Mol Cancer Ther 9:3315-21. 2010
    ..These observations open the way to clinical studies exploring the role of CYP1B1 gene polymorphisms for predicting tumor sensitivity to chemotherapy...
  30. ncbi request reprint Alterations in the expression of cytochrome c oxidase subunits in doxorubicin-resistant leukemia K562 cells
    Fabienne Grandjean
    Groupe Physiologie Moléculaire Mitochondriale et Immunitaire, Faculte de Medecine, UMR 6101, CNRS, 2 rue du Dr Marcland, 87025 Cedex, Limoges, France
    Biochem Pharmacol 63:823-31. 2002
    ..Our results seem to indicate compensatory mechanisms which highlight the complexity of regulatory systems of COX enzyme, involving coordinate regulation of both nuclear and mitochondrial subunit expression...
  31. ncbi request reprint Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel
    Nadège Nief
    Laboratoire de Pharmacologie des Agents Anticancéreux, Institut Bergonie, 33076 Bordeaux Cedex, France
    Eur J Cancer 43:955-62. 2007
    ..However, no significant correlation existed between fluorouracil cytotoxicity, as extracted from the NCI databases, and TYMS expression, activity or polymorphisms...
  32. ncbi request reprint Predicting drug response based on gene expression
    Jacques Robert
    Institut Bergonié and Université Victor Segalen Bordeaux 2, 229 Cours de l Argonne, 33076 Bordeaux, France
    Crit Rev Oncol Hematol 51:205-27. 2004
    ....
  33. ncbi request reprint Involvement of nonclassical MHC class Ib molecules in heat shock protein-mediated anti-tumor responses
    Ana Goyos
    Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Eur J Immunol 37:1494-501. 2007
    ..This study provides in vitro and in vivo evidence of the evolutionary conservation of class Ib involvement in anti-tumor CD8+ T cell responses...
  34. ncbi request reprint A chemotherapy-associated senescence bystander effect in breast cancer cells
    Xu Di
    Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298, USA
    Cancer Biol Ther 7:864-72. 2008
    ..Our study reveals a novel action of Adriamycin, which may contribute to its potent anti-breast cancer activity and lead to the discovery of additional therapeutic targets for the exploitation of a senescence bystander effect...
  35. doi request reprint Protein arginine (N)-methyl transferase 7 (PRMT7) as a potential target for the sensitization of tumor cells to camptothecins
    Vincent Verbiest
    INSERM U916, VINCO, Institut Bergonié and Université Victor Segalen Bordeaux 2, 33076 Bordeaux, France
    FEBS Lett 582:1483-9. 2008
    ..Finally, downregulation of the human PRMT7 could also sensitize HeLa cells to CPT, suggesting that it could be used as a target to potentiate CPT derivatives...
  36. ncbi request reprint Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel
    Valérie Le Morvan
    Laboratoire de Pharmacologie des Agents Anticancéreux, Institut Bergonie, 229 Cours de l Argonne, 33076 Bordeaux Cedex, France
    Pharmacogenomics 7:843-52. 2006
    ..We tested its potential interest for establishing relationships between the polymorphism of genes involved in drug metabolism and transport or in DNA repair, and drug cytotoxicity extracted from NCI databases...
  37. ncbi request reprint Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes
    Dominique Beulz-Riché
    Service de Pharmacologie et Centre Régional de Pharmacovigilance, CHU de la Cavale Blanche, Bd Tanguy Prigent, 29609 Brest Cedex, France
    Cancer Chemother Pharmacol 49:274-80. 2002
    ....
  38. ncbi request reprint Impact of EGFR gene polymorphisms on anticancer drug cytotoxicity in vitro
    Stéphane Puyo
    Universite de Bordeaux, Institut Bergonie, Bordeaux, France
    Mol Diagn Ther 12:225-34. 2008
    ..This study aims to analyze the relationships between specific EGFR functional polymorphisms and anticancer drug activity...
  39. ncbi request reprint Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart
    Joëlle Plandé
    Laboratoire de Pharmacologie des Agents Anticancéreux, Institut Bergonie, 229 Cours de l Argonne, 33076 Bordeaux Cedex, France
    Toxicol Lett 161:37-42. 2006
    ....
  40. ncbi request reprint Major improvement of the reference method of the French drug resistance network for P-glycoprotein detection in human haematological malignancies
    Sylvie Huet
    Dpt de Biologie Médicale, Laboratoire de Pharmacologie des Agents Anticancéreux, CNRS FRE 2618, Universite Victor Segalen Bordeaux 2 and Institut Bergonie, 229 cours de l rgonne, F 33076 Bordeaux cedex, France
    Leuk Res 29:1029-37. 2005
    ..Pgp was specifically detected in pathological blood cells in the six positive samples...
  41. ncbi request reprint Quantification of the expression of multidrug resistance-related genes in human tumour cell lines grown with free doxorubicin or doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres
    Armelle Laurand
    Laboratoire de Pharmacologie des Agents Anticancéreux, Universite Victor Segalen Bordeaux 2, and Institut Bergonié, 229 Cours de l Argonne, 33076 Bordeaux, France
    Anticancer Res 24:3781-8. 2004
    ..Our results show that several mechanisms may be involved in the acquisition of drug resistance and that drug encapsulation markedly alters or delays these processes...
  42. ncbi request reprint [Recent advances in pharmacogenomics in oncology]
    Jacques Robert
    Universite Victor Segalen, Institut Bergonie, Bordeaux, France
    Bull Cancer 91:19-28. 2004
    ..Clinical trials, first on a retrospective basis, then performed prospectively, are implemented to validate this approach...
  43. ncbi request reprint Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells
    Eliza Munteanu
    Laboratoire de Physiologie Mitochondriale, EA 3842 Faculté de Médecine, Limoges, France
    Biochem Pharmacol 71:1162-74. 2006
    ..A potential role for mitochondrial P-gp in MDR cells would be to protect the nucleus from doxorubicin. This is the first demonstration of the presence and functional activity of P-gp in mitochondria of MDR cells...
  44. ncbi request reprint [New concepts for the study of anticancer drug resistance]
    Jacques Robert
    Institut Bergonie, 229, cours de l Argonne, 33076 Bordeaux Cedex, France
    Bull Cancer 89:17-22. 2002
    ..This may allow the identification of drug-response genes (whose expression is altered by the drug) and of signaling and metabolic pathways involved in drug activity...
  45. ncbi request reprint Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research
    Antoine Vekris
    DiGEM S A, Bordeaux, France
    Cancer Res 64:356-62. 2004
    ..Public databases mining, therefore, appears to be a valuable tool for the identification of determinants of anticancer drug activity in tumors...
  46. ncbi request reprint Xenopus as an experimental model for studying evolution of hsp--immune system interactions
    Jacques Robert
    Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Methods 32:42-53. 2004
    ..Finally, techniques to study modalities of expression of the endoplasmic reticulum resident gp96 at the cell surface of tumor and normal lymphocytes are considered...
  47. ncbi request reprint Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38
    Virginie Charasson
    Laboratory of Pharmacology of Anticancer Agents, Institut Bergonié and Université Victor Segalen Bordeaux 2, 33076 Bordeaux Cedex, France
    Clin Pharmacol Ther 76:528-35. 2004
    ..We have explored this possibility in looking for single nucleotide polymorphisms and their functional consequence...
  48. ncbi request reprint 8-O-Azeloyl-14-benzoylaconine: a new alkaloid from the roots of Aconitum karacolicum Rapcs and its antiproliferative activities
    Ainura Chodoeva
    Laboratoire de pharmacologie des médicaments anticancéreux, Institut Bergonie, Bordeaux, France
    Bioorg Med Chem 13:6493-501. 2005
    ..It presents in vitro cytotoxicity with an IC(50) of about 10-20 microM, which warrants further investigation on its possible interest in cancer chemotherapy...
  49. ncbi request reprint Ontogeny of Xenopus NK cells in the absence of MHC class I antigens
    Trudy L Horton
    School of Biological and Biomedical Sciences, University of Durham, Durham DH1 3LE, UK
    Dev Comp Immunol 27:715-26. 2003
    ....
  50. ncbi request reprint Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines
    Valerie Pavillard
    Universite Victor Segalen Bordeaux 2 and Institut Bergonie, 229 Cours de l Argonne, 33076 Bordeaux, France
    Cancer Chemother Pharmacol 49:329-35. 2002
    ....
  51. ncbi request reprint Synthesis and antiproliferative activity of aryl- and heteroaryl-hydrazones derived from xanthone carbaldehydes
    Martine Varache-Lembège
    Laboratoire de Chimie Therapeutique, EA2962, Faculte de Pharmacie, Universite Victor Segalen Bordeaux 2, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Eur J Med Chem 43:1336-43. 2008
    ..This unusual cytotoxicity profile led to the hypothesis that these molecules could be endowed with a mechanism of action distinct to that of doxorubicin...
  52. ncbi request reprint Conservation of IL-6 trans-signaling mechanisms controlling L-selectin adhesion by fever-range thermal stress
    Michelle M Appenheimer
    Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263 0001, USA
    Eur J Immunol 37:2856-67. 2007
    ....
  53. ncbi request reprint Determination of drug interactions occurring with the metabolic pathways of irinotecan
    Virginie Charasson
    Institut Bergonie, Bordeaux Cedex, France
    Drug Metab Dispos 30:731-3. 2002
    ....
  54. ncbi request reprint Genetic polymorphisms of the XPG and XPD nucleotide excision repair genes in sarcoma patients
    Valérie Le Morvan
    Laboratory of Pharmacology of Anticancer Agents EA 515, Institut Bergonié and Université Victor Segalen Bordeaux 2, Bordeaux, France
    Int J Cancer 119:1732-5. 2006
    ..For XPD, both alleles were lost with a similar frequency. Our results raise the potential implication of the XPG Asp1104His polymorphism in the occurrence of chromosomal translocations associated with specific subtypes of sarcomas...
  55. ncbi request reprint A phase II study for the evaluation of quinine as a modulator of multidrug resistance in non-Hodgkin's lymphoma
    Pierre Soubeyran
    Departement de Medecine, Institut Bergonie, Bordeaux, France
    Eur J Cancer 43:53-4. 2007
  56. ncbi request reprint Functional analysis of the gene expression profiles of colorectal cancer cell lines in relation to oxaliplatin and cisplatin cytotoxicity
    Delphine Meynard
    Laboratoire de Pharmacologie des Agents Anticancéreux, Institut Bergonie, CNRS FRE 2618, Universite Victor Segalen Bordeaux 2, 33076 Bordeaux Cedex, France
    Oncol Rep 17:1213-21. 2007
    ..Based on the functional analysis, we hypothesized that oxaliplatin would specifically form protein adducts during synthesis, thus exposing their thiol groups, which are known to be especially vulnerable to reactive oxygen species...
  57. ncbi request reprint Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study
    Valerie Pavillard
    Laboratoire de Pharmacologie des Agents Anticancéreux, Institut Bergonié et Université Victor Segalen Bordeaux 2, 229, cours de l Argonne 33076 Bordeaux cedex, France
    Anticancer Res 24:579-85. 2004
    ..Irinotecan is a camptothecin derivative requiting carboxylesterase activation to SN-38, which interacts with its target enzyme, topoisomerase I...
  58. ncbi request reprint Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene
    Ricardo Bellott
    Laboratoire de Pharmacologie des Agents Anticancéreux, Institut Bergonie, Universite Victor Segalen Bordeaux 2, France
    Cancer Chemother Pharmacol 61:481-8. 2008
    ....